Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,822 shares of the company’s stock after selling 200 shares during the period. Flagship Harbor Advisors LLC’s holdings in AstraZeneca were worth $512,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. FMR LLC boosted its position in shares of AstraZeneca by 1.1% in the third quarter. FMR LLC now owns 23,117,447 shares of the company’s stock valued at $1,801,080,000 after acquiring an additional 258,477 shares during the period. Franklin Resources Inc. grew its position in AstraZeneca by 8.7% during the third quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock worth $1,492,649,000 after buying an additional 1,522,715 shares in the last quarter. Fisher Asset Management LLC grew its position in AstraZeneca by 5.3% during the third quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock worth $816,509,000 after buying an additional 524,175 shares in the last quarter. Clearbridge Investments LLC raised its holdings in shares of AstraZeneca by 5.8% in the 2nd quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock valued at $265,458,000 after acquiring an additional 186,010 shares in the last quarter. Finally, Bank of Montreal Can boosted its position in shares of AstraZeneca by 109.6% during the 3rd quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock valued at $238,397,000 after acquiring an additional 1,605,758 shares during the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.
AstraZeneca Price Performance
Shares of AstraZeneca stock opened at $69.59 on Wednesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a fifty day moving average of $66.58 and a 200-day moving average of $74.08. The stock has a market capitalization of $215.80 billion, a price-to-earnings ratio of 33.30, a price-to-earnings-growth ratio of 1.13 and a beta of 0.46.
Analyst Ratings Changes
AZN has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, AstraZeneca currently has an average rating of “Buy” and an average price target of $89.75.
View Our Latest Stock Report on AZN
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
- Five stocks we like better than AstraZeneca
- Consumer Staples Stocks, Explained
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- What Does the Future Hold for Eli Lilly?
- Why is the Ex-Dividend Date Significant to Investors?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.